No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
Publication Title
Leukemia & lymphoma
Document Type
Article
Publication Date
12-10-2020
Keywords
Hemorrhage; PI3K inhibitor; anticoagulant; antiplatelet; thrombocytopenia
Abstract
The advent of novel B-cell receptor pathway targeting agents like ibrutinib dramatically changed management of B-cell malignancies. However, with concomitant anticoagulation (AC) and antiplatelet (AP) therapy, ibrutinib is associated with increased bleeding. This
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
COinS
